Worth reading
25Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
This company splitCounterpartyPENTAX Medical 合同会社
Disclosing companyHOYA CORPORATION
TimelineThe spacing between the points is proportional to the actual number of days.
Target company
The Company's endoscopy business in Japan
Location Japan
Impact on Business Performance
The change in the effective date described above will have no impact on consolidated results.
Procedures and assumptions
Conditions Precedent to ExecutionResponding to administrative procedures and other matters in various countries
Management structure after acquisitionBy the effective date, PENTAX Medical 合同会社 is expected to become a wholly owned subsidiary of HOYA Holdings N.V., the Company's wholly owned subsidiary.
| Item | Details |
|---|---|
| Transaction name | This company split |
| Counterparty name | PENTAX Medical 合同会社 |
| Business Description of the Subject Company | The Company's endoscopy business in Japan |
| Location of the Subject Company | Japan |
| Impact on Business Performance | The change in the effective date described above will have no impact on consolidated results. |
| Contract Date | 26 March 2026 |
| Execution Date / Effective Date | 1 August 2026 (scheduled) |
| Conditions Precedent to Execution | Responding to administrative procedures and other matters in various countries |
| Management structure after acquisition | By the effective date, PENTAX Medical 合同会社 is expected to become a wholly owned subsidiary of HOYA Holdings N.V., the Company's wholly owned subsidiary. |
Items this document does not state (23)
Name of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionValuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because responding to administrative procedures and other matters in various countries is expected to take longer than anticipated.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.